31 Results for "

face

" in MedChemExpress (MCE) Product Catalog:
Products (31)

31 Results for "face" in MCE Product Catalog:

Cat. No.: HY-P810736
Synonyms: FAE; face; ELOVL fatty acid elongase 6; ELOVL FA elongase 6

Host:  

Rabbit

Application:  

WB, IHC-P

Reactivity:  

Human, Mouse

loading...
    loading...
Cat. No.: HY-P810996
Synonyms: face, LCE, ELOVL6, Very long chain fatty acid elongase 6, 3-keto acyl-CoA synthase ELOVL6, ELOVL fatty acid elongase 6, Elongation of very long chain fatty acids protein 6, Fatty acid elongase 2, Fatty acyl-CoA elongase, Long-chain fatty-acyl elongase, Very long chain 3-ketoacyl-CoA synthase 6, Very long chain 3-oxoacyl-CoA synthase 6, ELOVL FA elongase 6, hELO2

Host:  

Rabbit

Application:  

WB, ICC/IF

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-17571BS
Synonyms: α-Hypophamine-d10 TFA; Oxytocic hormone-d10 TFA
Oxytocin-d10 TFA (α-Hypophamine-d10 TFA) is the deuterium labeled Oxytocin TFA (HY-17571B). Oxytocin (α-Hypophamine; Oxytocic hormone) is a pleiotropic, hypothalamic peptide known for facilitating parturition, lactation, and prosocial behaviors. Oxytocin can function as a stress-coping molecule with anti-inflammatory, antioxidant, and protective effects especially in the face of adversity or trauma.
loading...
    loading...
Cat. No.: HY-17571S
Synonyms: α-Hypophamine-13C6,15N TFA; Oxytocic hormone-13C6,15N TFA
Oxytocin- 13C6, 15N (α-Hypophamine- 13C6, 15N) TFA is the 13C- and 15N-labeled Oxytocin TFA. Oxytocin (α-Hypophamine; Oxytocic hormone) is a pleiotropic, hypothalamic peptide known for facilitating parturition, lactation, and prosocial behaviors. Oxytocin can function as a stress-coping molecule with anti-inflammatory, antioxidant, and protective effects especially in the face of adversity or trauma.
loading...
    loading...
Cat. No.: HY-110287R
CAS No.: 300815-04-7
Research Areas:  

Cancer

Apcin (Standard) is the analytical standard of Apcin (HY-110287). This product is intended for research and analytical applications. Apcin, a ligand of Cdc20, is a potent and competitive anaphase-promoting complex/cyclosome (APC/C(Cdc20)) E3 ligase activity inhibitor. Apcin competitively inhibits APC/C-dependent ubiquitylation by binding to Cdc20 and preventing substrate recognition. Apcin occupes the D-box-binding pocket on the side face of the WD40-domain and can prolong mitosis .
loading...
    loading...
Cat. No.: HY-184616
Nanomaterials with sizes ranging from 1 to 100 nm are generally referred to as nanocrystals. The preparation of platinum nanocrystals with controllable morphology was first reported in 1996. Pt, Ag, Au, Rh, and other nanocrystals have been synthesized using various methods. Platinum has a face-centered cubic (fcc) structure, but unlike Ag, Au, and Pd, it rarely forms twins; most platinum nanocrystals are single-crystal structures. XFJ116 platinum nanoparticles were prepared via a chemical reduction method, exhibiting uniform size and good dispersibility, and can also provide platinum nanoparticles with amino and carboxyl terminator modifications.
loading...
    loading...
Cat. No.: HY-187364
CAS No.: 3050594-88-9
Research Areas:  

Inflammation/Immunology

TRPV4 antagonist-7 is a potent and selective TRPV4 antagonist with an IC50 of 0.2 nM against human targets. TRPV4 antagonist-7 binds to the voltage-sensor-like domain cavity of TRPV4 and inhibits channel activity through the formation of salt bridges, hydrogen bonds, and edge-to-face π-stacking interactions. TRPV4 antagonist-7 induces phospholipid accumulation in HepG2 C3A cells in vitro with an IC50 of 3.8 μM, and exhibits moderate inhibitory effects on CYP2D6 with an IC50 of 5.1 μM. TRPV4 antagonist-7 dose-dependently inhibits GSK1016790A (HY-19608)-induced bronchoconstriction in rats and cough in guinea pigs. TRPV4 antagonist-7 can be used in studies related to respiratory system diseases .
loading...
    loading...
Cat. No.: HY-L245
2,256 compounds

At the forefront of innovative drug discovery, every medicinal chemist faces the challenge of rapidly identifying high-quality hit compounds from vast repositories of chemical resources.

The MCE Natural Product Diversity Scaffold Library is the result of a streamlined optimization process built upon our existing natural product collection. Adhering to the rigorous selection principle of "retaining only one representative compound per BMS scaffold", we have concentrated the diversity of thousands of compounds into a high-value, low-redundancy core set containing 2,256 compounds. All compounds are derived from natural sources, inheriting their inherent advantages of structural complexity and drug-likeness. By eliminating redundancy, the library size is significantly reduced without any compromise to chemical diversity. This approach effectively lowers the cost and time required for primary screening while simplifying downstream data analysis and structure-activity relationship (SAR) studies.

Cat. No.: HY-L0119V
3,253 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

The PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics. The designs cover β-turn / loop mimetics and α-helix mimetics. Since helices present at the interface in 62% of all protein-protein interactions. This library focused on designs including mimics with the substitution geometry of an a-helices, as well as designs that mimic the location of “hot-spot” side chains in helix-mediated PPIs.

Cat. No.: HY-L142
159 compounds

Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.

Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.

MCE supplies a unique collection of 159 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Cat. No.: HY-L109
826 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 826 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.